Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 699
Filtrar
1.
AAPS PharmSciTech ; 25(6): 154, 2024 Jul 03.
Artículo en Inglés | MEDLINE | ID: mdl-38961012

RESUMEN

Berberine is used in the treatment of metabolic syndrome and its low solubility and very poor oral bioavailability of berberine was one of the primary hurdles for its market approval. This study aimed to improve the solubility and bioavailability of berberine by preparing pellet formulations containing drug-excipient complex (obtained by solid dispersion). Berberine-excipient solid dispersion complexes were obtained with different ratios by the solvent evaporation method. The maximum saturation solubility test was performed as a key factor for choosing the optimal complex for the drug-excipient. The properties of these complexes were investigated by FTIR, DSC, XRD and dissolution tests. The obtained pellets were evaluated and compared in terms of pelletization efficiency, particle size, mechanical strength, sphericity and drug release profile in simulated media of gastric and intestine. Solid-state analysis showed complex formation between the drug and excipients used in solid dispersion. The optimal berberine-phospholipid complex showed a 2-fold increase and the optimal berberine-gelucire and berberine-citric acid complexes showed more than a 3-fold increase in the solubility of berberine compared to pure berberine powder. The evaluation of pellets from each of the optimal complexes showed that the rate and amount of drug released from all pellet formulations in the simulated gastric medium were significantly lower than in the intestine medium. The results of this study showed that the use of berberine-citric acid or berberine-gelucire complex could be considered a promising technique to increase the saturation solubility and improve the release characteristics of berberine from the pellet formulation.


Asunto(s)
Berberina , Química Farmacéutica , Composición de Medicamentos , Liberación de Fármacos , Excipientes , Tamaño de la Partícula , Solubilidad , Berberina/química , Berberina/administración & dosificación , Berberina/farmacocinética , Excipientes/química , Composición de Medicamentos/métodos , Química Farmacéutica/métodos , Disponibilidad Biológica , Espectroscopía Infrarroja por Transformada de Fourier/métodos , Polvos/química , Difracción de Rayos X/métodos , Rastreo Diferencial de Calorimetría/métodos
2.
Signal Transduct Target Ther ; 9(1): 183, 2024 Jul 08.
Artículo en Inglés | MEDLINE | ID: mdl-38972904

RESUMEN

Helicobacter pylori (H. pylori) is currently recognized as the primary carcinogenic pathogen associated with gastric tumorigenesis, and its high prevalence and resistance make it difficult to tackle. A graph neural network-based deep learning model, employing different training sets of 13,638 molecules for pre-training and fine-tuning, was aided in predicting and exploring novel molecules against H. pylori. A positively predicted novel berberine derivative 8 with 3,13-disubstituted alkene exhibited a potency against all tested drug-susceptible and resistant H. pylori strains with minimum inhibitory concentrations (MICs) of 0.25-0.5 µg/mL. Pharmacokinetic studies demonstrated an ideal gastric retention of 8, with the stomach concentration significantly higher than its MIC at 24 h post dose. Oral administration of 8 and omeprazole (OPZ) showed a comparable gastric bacterial reduction (2.2-log reduction) to the triple-therapy, namely OPZ + amoxicillin (AMX) + clarithromycin (CLA) without obvious disturbance on the intestinal flora. A combination of OPZ, AMX, CLA, and 8 could further decrease the bacteria load (2.8-log reduction). More importantly, the mono-therapy of 8 exhibited comparable eradication to both triple-therapy (OPZ + AMX + CLA) and quadruple-therapy (OPZ + AMX + CLA + bismuth citrate) groups. SecA and BamD, playing a major role in outer membrane protein (OMP) transport and assembling, were identified and verified as the direct targets of 8 by employing the chemoproteomics technique. In summary, by targeting the relatively conserved OMPs transport and assembling system, 8 has the potential to be developed as a novel anti-H. pylori candidate, especially for the eradication of drug-resistant strains.


Asunto(s)
Antibacterianos , Berberina , Aprendizaje Profundo , Helicobacter pylori , Helicobacter pylori/efectos de los fármacos , Berberina/farmacología , Berberina/química , Berberina/farmacocinética , Antibacterianos/farmacología , Antibacterianos/química , Humanos , Infecciones por Helicobacter/tratamiento farmacológico , Infecciones por Helicobacter/microbiología , Pruebas de Sensibilidad Microbiana , Farmacorresistencia Bacteriana Múltiple/efectos de los fármacos , Farmacorresistencia Bacteriana Múltiple/genética , Animales , Omeprazol/farmacología , Claritromicina/farmacología , Amoxicilina/farmacología
3.
J Mol Model ; 30(8): 260, 2024 Jul 09.
Artículo en Inglés | MEDLINE | ID: mdl-38981921

RESUMEN

CONTEXT: Diabetes mellitus (DM) is a metabolic disorder disease that causes hyperglycemia conditions and associated with various chronic complications leading to mortality. Due to high toxicity of conventional diabetic drugs, the exploration of natural compounds as alternative diabetes treatments has been widely carried out. Previous in silico studies have highlighted berberine, a natural compound, as a promising alternative in antidiabetic therapy, potentially acting through various pathways, including the inhibition of the FOXO1 transcription factor in the gluconeogenesis pathway. However, the specific mechanism by which berberine interacts with FOXO1 remains unclear, and research in this area is relatively limited. Therefore, this study aims to determine the stability of berberine structure with FOXO1 based on RMSD, RMSF, binding energy, and trajectory analysis to determine the potential of berberine to inhibit the gluconeogenesis pathway. This research was conducted by in silico method with molecular docking using AutoDock4.2 and molecular dynamics study using Amber20, then visualized by VMD. METHODS: Docking between ligand and FOXO1 receptor was carried out with Autodock4.2. For molecular dynamics simulations, the force fields of DNA.OL15, protein.ff14SB, gaff2, and tip3p were used.


Asunto(s)
Berberina , Proteína Forkhead Box O1 , Hipoglucemiantes , Simulación del Acoplamiento Molecular , Simulación de Dinámica Molecular , Berberina/química , Berberina/farmacología , Hipoglucemiantes/química , Hipoglucemiantes/farmacología , Proteína Forkhead Box O1/metabolismo , Proteína Forkhead Box O1/química , Humanos , Unión Proteica , Sitios de Unión , Ligandos
4.
Drug Des Devel Ther ; 18: 2847-2868, 2024.
Artículo en Inglés | MEDLINE | ID: mdl-39006190

RESUMEN

Purpose: This study aimed to delineate the molecular processes underlying the therapeutic effects of berberine on UC by employing network pharmacology tactics, molecular docking, and dynamic simulations supported by empirical validations both in vivo and in vitro. Patients and Methods: We systematically screened potential targets and relevant pathways affected by berberine for UC treatment from comprehensive databases, including GeneCards, DisGeNET, and GEO. Molecular docking and simulation protocols were used to assess the interaction stability between berberine and its principal targets. The predictions were validated using both a DSS-induced UC mouse model and a lipopolysaccharide (LPS)-stimulated NCM460 cellular inflammation model. Results: Network pharmacology analysis revealed the regulatory effect of the TLR4/NF-κB/HIF-1α pathway in the ameliorative action of berberine in UC. Docking and simulation studies predicted the high-affinity interactions of berberine with pivotal targets: TLR4, NF-κB, HIF-1α, and the HIF inhibitor KC7F2. Moreover, in vivo analyses demonstrated that berberine attenuates clinical severity, as reflected by decreased disease activity index (DAI) scores, reduced weight loss, and mitigated intestinal inflammation in DSS-challenged mice. These outcomes include suppression of the proinflammatory cytokines IL-6 and TNF-α and downregulation of TLR4/NF-κB/HIF-1α mRNA and protein levels. Correspondingly, in vitro findings indicate that berberine decreases cellular inflammatory injury and suppresses TLR4/NF-κB/HIF-1α signaling, with notable effectiveness similar to that of the HIF-1α inhibitor KC7F2. Conclusion: Through network pharmacology analysis and experimental substantiation, this study confirmed that berberine enhances UC treatment outcomes by inhibiting the TLR4/NF-κB/HIF-1α axis, thereby mitigating inflammatory reactions and improving colonic pathology.


Asunto(s)
Berberina , Colitis Ulcerosa , Biología Computacional , Subunidad alfa del Factor 1 Inducible por Hipoxia , FN-kappa B , Receptor Toll-Like 4 , Berberina/farmacología , Berberina/química , Receptor Toll-Like 4/metabolismo , Receptor Toll-Like 4/antagonistas & inhibidores , Subunidad alfa del Factor 1 Inducible por Hipoxia/metabolismo , Subunidad alfa del Factor 1 Inducible por Hipoxia/antagonistas & inhibidores , FN-kappa B/metabolismo , FN-kappa B/antagonistas & inhibidores , Animales , Ratones , Humanos , Colitis Ulcerosa/tratamiento farmacológico , Colitis Ulcerosa/metabolismo , Colitis Ulcerosa/inducido químicamente , Colitis Ulcerosa/patología , Simulación del Acoplamiento Molecular , Lipopolisacáridos/farmacología , Lipopolisacáridos/antagonistas & inhibidores , Masculino , Sulfato de Dextran , Ratones Endogámicos C57BL , Modelos Animales de Enfermedad , Farmacología en Red
5.
J Colloid Interface Sci ; 672: 63-74, 2024 Oct 15.
Artículo en Inglés | MEDLINE | ID: mdl-38830319

RESUMEN

Multidrug-resistant (MDR) bacteria-infected wound healing remains greatly challenging, especially in diabetic patients. Herein, a novel nano-drug delivery based on endogenous glucose-driven cascade reaction is proposed for boosting MDR bacteria-infected diabetic wound healing with high efficacy by improving wound microenvironment and enhancing photodynamic antibacterial activity. The composite nanoagent is first self-assembled by integrating berberine (BBR) and epigallocatechin gallate (EGCG) from natural plant extracts, named as BENPs, which is successively coated with manganese dioxide nanoshells (MnO2 NSs) and glucose oxidase (GOX) to form the final BEMGNPs. The cascade reaction is triggered by glucose at the wound site of diabetes which is specifically catalyzed by GOX in the BEMGNPs to produce gluconic acid and hydrogen peroxide (H2O2). That is subsequently to decompose MnO2 NSs in the BEMGNPs to generate oxygen (O2). The BEMGNPs as photosensitizers effectively produce reactive oxygen species (ROS) to enhance the eradication of bacteria with the assistance of O2. Under the synergistic function of the cascaded reaction, the BEMGNPs present excellent antibacterial efficacy even for MDR bacteria. The in vivo experiments explicitly validate that the constructed nano-drug delivery can augment the MDR bacteria-infected diabetic wound healing with excellent biosafety. The as-proposed strategy provides an instructive way to combat ever-threatening MDR bacteria, which particularly is beneficial for diabetic patients.


Asunto(s)
Antibacterianos , Farmacorresistencia Bacteriana Múltiple , Glucosa , Compuestos de Manganeso , Óxidos , Cicatrización de Heridas , Cicatrización de Heridas/efectos de los fármacos , Antibacterianos/farmacología , Antibacterianos/química , Compuestos de Manganeso/química , Compuestos de Manganeso/farmacología , Óxidos/química , Óxidos/farmacología , Glucosa/química , Glucosa/metabolismo , Farmacorresistencia Bacteriana Múltiple/efectos de los fármacos , Animales , Glucosa Oxidasa/química , Glucosa Oxidasa/farmacología , Glucosa Oxidasa/metabolismo , Catequina/química , Catequina/farmacología , Catequina/análogos & derivados , Catequina/administración & dosificación , Ratones , Berberina/farmacología , Berberina/química , Pruebas de Sensibilidad Microbiana , Diabetes Mellitus Experimental/tratamiento farmacológico , Fármacos Fotosensibilizantes/farmacología , Fármacos Fotosensibilizantes/química , Escherichia coli/efectos de los fármacos , Tamaño de la Partícula , Humanos , Nanopartículas/química , Sistema de Administración de Fármacos con Nanopartículas/química , Sistema de Administración de Fármacos con Nanopartículas/farmacología , Staphylococcus aureus/efectos de los fármacos
6.
Int J Biol Macromol ; 273(Pt 1): 132737, 2024 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-38825265

RESUMEN

Polysaccharide-based drug delivery systems are in high demand due to their biocompatibility, non-toxicity, and low-cost. In this study, sialic acid receptor targeted 4-carboxy phenylboronic acid modified pullulan-stearic acid conjugate (4-cPBA-PUL-SA) was synthesized and characterized for the delivery of Berberine (BBR). BBR-loaded 4-cPBA-PUL-SA nanoparticles (BPPNPs) were monodispersed (PDI: 0.238 ± 0.07), with an average hydrodynamic particle size of 191.6 nm and 73.6 % encapsulation efficiency. BPPNPs showed controlled BBR release and excellent colloidal stability, indicating their potential for drug delivery application. The cytotoxicity results indicated that BPPNPs exhibited dose and time-dependent cytotoxicity against human epidermoid carcinoma cells (A431) as well as 3D spheroids. Targeted BPPNPs demonstrated significantly higher anticancer activity compared to BBR and non-targeted BPNPs. The IC50 values for BPPNPs (2.29 µg/ml) were significantly lower than BPNPs (4.13 µg/ml) and BBR (19.61 µg/ml), indicating its potential for skin cancer treatment. Furthermore, CSLM images of A431 cells and 3D spheroids demonstrated that BPPNPs have higher cellular uptake and induced apoptosis compared to free BBR and BPNPs. In conclusion, BPPNPs demonstrate promising potential as an effective drug delivery system for skin cancer therapy.


Asunto(s)
Antineoplásicos , Berberina , Ácidos Borónicos , Glucanos , Nanopartículas , Neoplasias Cutáneas , Esferoides Celulares , Humanos , Berberina/química , Berberina/farmacología , Glucanos/química , Glucanos/farmacología , Ácidos Borónicos/química , Nanopartículas/química , Antineoplásicos/farmacología , Antineoplásicos/química , Línea Celular Tumoral , Esferoides Celulares/efectos de los fármacos , Neoplasias Cutáneas/tratamiento farmacológico , Neoplasias Cutáneas/patología , Tamaño de la Partícula , Portadores de Fármacos/química , Liberación de Fármacos , Supervivencia Celular/efectos de los fármacos
7.
Int J Nanomedicine ; 19: 5297-5316, 2024.
Artículo en Inglés | MEDLINE | ID: mdl-38859955

RESUMEN

Propose: Oxyberberine (OBB), one of the main metabolites of berberine derived from intestinal and erythrocyte metabolism, exhibits appreciable anti-hyperuricemic activity. However, the low water solubility and poor plasma concentration-effect relationship of OBB hamper its development and utilization. Therefore, an OBB-hydroxypropyl-ß-cyclodextrin (HP-ß-CD) supersaturated drug delivery system (SDDS) was prepared and characterized in this work. Methods: OBB-HP-ß-CD SDDS was prepared using the ultrasonic-solvent evaporation method and characterized. Additionally, the in vitro and in vivo release experiments were conducted to assess the release kinetics of OBB-HP-ß-CD SDDS. Subsequently, the therapeutic efficacy of OBB-HP-ß-CD SDDS on hyperuricemia (HUA) was investigated by means of histopathological examination and evaluation of relevant biomarkers. Results: The results of FT-IR, DSC, PXRD, NMR and molecular modeling showed that the crystallized form of OBB was transformed into an amorphous OBB-HP-ß-CD complex. Dynamic light scattering indicated that this system was relatively stable and maintained by formation of nanoaggregates with an average diameter of 23 nm. The dissolution rate of OBB-HP-ß-CD SDDS was about 5 times higher than that of OBB raw material. Furthermore, the AUC0-t of OBB-HP-ß-CD SDDS (10.882 µg/mL*h) was significantly higher than that of the raw OBB counterpart (0.701 µg/mL*h). The oral relative bioavailability of OBB-HP-ß-CD SDDS was also enhanced by 16 times compared to that of the raw material. Finally, in vivo pharmacodynamic assay showed the anti-hyperuricemic potency of OBB-HP-ß-CD SDDS was approximately 5-10 times higher than that of OBB raw material. Conclusion: Based on our findings above, OBB-HP-ß-CD SDDS proved to be an excellent drug delivery system for increasing the solubility, dissolution, bioavailability, and anti-hyperuricemic potency of OBB.


Asunto(s)
Berberina , Animales , Berberina/farmacocinética , Berberina/química , Berberina/administración & dosificación , Berberina/farmacología , Masculino , 2-Hidroxipropil-beta-Ciclodextrina/química , 2-Hidroxipropil-beta-Ciclodextrina/farmacocinética , Hiperuricemia/tratamiento farmacológico , Hiperuricemia/sangre , Sistemas de Liberación de Medicamentos/métodos , Solubilidad , Nanopartículas/química , Ratas , Ratas Sprague-Dawley , Liberación de Fármacos , Tamaño de la Partícula , Disponibilidad Biológica , Ácido Úrico/química , Ácido Úrico/sangre
8.
Sci Rep ; 14(1): 14924, 2024 06 28.
Artículo en Inglés | MEDLINE | ID: mdl-38942824

RESUMEN

Oxyberberine (OBB) is a significant natural compound, with excellent hepatoprotective properties. However, the poor water solubility of OBB hinders its release and absorption thus resulting in low bioavailability. To overcome these drawbacks of OBB, amorphous spray-dried powders (ASDs) of OBB were formulated. The dissolution, characterizations, and pharmacokinetics of OBB-ASDs formulation were investigated, and its hepatoprotective action was disquisitive in the D-GalN/LPS-induced acute liver injury (ALI) mouse model. The characterizations of OBB-ASDs indicated that the crystalline form of OBB active pharmaceutical ingredients (API) was changed into an amorphous form in OBB-ASDs. More importantly, OBB-ASDs showed a higher bioavailability than OBB API. In addition, OBB-ASDs treatment restored abnormal histopathological changes, improved liver functions, and relieved hepatic inflammatory mediators and oxidative stress in ALI mice. The spray drying techniques produced an amorphous form of OBB, which could significantly enhance the bioavailability and exhibit excellent hepatoprotective effects, indicating that the OBB-ASDs can exhibit further potential in hepatoprotective drug delivery systems. Our results provide guidance for improving the bioavailability and pharmacological activities of other compounds, especially insoluble natural compounds. Meanwhile, the successful development of OBB-ASDs could shed new light on the research process of poorly soluble medicine.


Asunto(s)
Berberina , Disponibilidad Biológica , Receptor Toll-Like 4 , Animales , Receptor Toll-Like 4/metabolismo , Ratones , Berberina/farmacología , Berberina/química , Berberina/uso terapéutico , Masculino , Solubilidad , Hígado/metabolismo , Hígado/efectos de los fármacos , Hígado/patología , Enfermedad Hepática Inducida por Sustancias y Drogas/tratamiento farmacológico , Enfermedad Hepática Inducida por Sustancias y Drogas/metabolismo , Enfermedad Hepática Inducida por Sustancias y Drogas/patología , Enfermedad Hepática Inducida por Sustancias y Drogas/prevención & control , Modelos Animales de Enfermedad , Estrés Oxidativo/efectos de los fármacos , Sustancias Protectoras/farmacología , Sustancias Protectoras/química , Lipopolisacáridos , Polvos , Sistemas de Liberación de Medicamentos
9.
ACS Biomater Sci Eng ; 10(7): 4347-4358, 2024 Jul 08.
Artículo en Inglés | MEDLINE | ID: mdl-38841860

RESUMEN

In order to improve the effectiveness of tumor treatment and reduce the toxic side effects of drugs, we formed carrier-free multifunctional nanoparticles (BI NPs) by noncovalent interaction of berberine hydrochloride and IR780. BI NPs possessed the synergistic effects of promoting apoptosis, inhibiting proliferation and metastasis of tumors, and phototherapeutic treatment. Dispersive and passive targeting ability retention (EPR) effects of BI NPs on tumor sites in vivo could be monitored by fluorescence imaging. In addition, BI NPs exhibited effective reactive oxygen species (ROS) generation and photothermal conversion capabilities, photodynamic therapy (PDT), and photothermal therapy (PTT). Importantly, BI NPs inhibit tumor suppression through the AMPK/PI3K/AKT signaling pathway to inhibit tumor proliferation and metastasis. BI NPs not only have efficient in vivo multimodal therapeutic effects but also have good biosafety and potential clinical applications.


Asunto(s)
Apoptosis , Carcinoma Hepatocelular , Proliferación Celular , Neoplasias Hepáticas , Nanomedicina , Nanopartículas , Apoptosis/efectos de los fármacos , Carcinoma Hepatocelular/tratamiento farmacológico , Carcinoma Hepatocelular/patología , Neoplasias Hepáticas/tratamiento farmacológico , Neoplasias Hepáticas/patología , Humanos , Proliferación Celular/efectos de los fármacos , Animales , Nanopartículas/química , Nanopartículas/uso terapéutico , Nanomedicina/métodos , Ratones , Especies Reactivas de Oxígeno/metabolismo , Fotoquimioterapia/métodos , Berberina/farmacología , Berberina/química , Berberina/uso terapéutico , Terapia Fototérmica , Ratones Endogámicos BALB C , Línea Celular Tumoral , Antineoplásicos/farmacología , Antineoplásicos/química , Antineoplásicos/uso terapéutico
10.
J Biomed Mater Res B Appl Biomater ; 112(7): e35439, 2024 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-38923766

RESUMEN

Sensorineural hearing loss (SNHL) is mainly caused by injury or loss of hair cells (HCs) and associated spiral ganglion neurons (SGNs) in the inner ear. At present, there is still no effective treatment for SNHL in clinic. Recently, advances in organoid bring a promising prospect for research and treatment of SNHL. Meanwhile, three-dimensional (3D) printing provides a tremendous opportunity to construct versatile organoids for tissue engineering and regenerative medicine. In this study, gelatin (Gel), sodium alginate (SA), and polyvinyl alcohol (PVA) were used to fabricate biomimetic scaffold through 3D printing. The organ of Corti derived from neonatal mice inner ear was seeded on the PVA/Gel/SA scaffold to construct organ of Corti organoid. Then, the organ of Corti organoid was used to study the potential protective effects of berberine sulfate on neomycin-juried auditory HCs and SGNs. The results showed that the PVA/Gel/SA biomimetic 3D scaffolds had good cytocompatibilities and mechanical properties. The constructed organoid could maintain organ of Corti activity well in vitro. In addition, the injury intervention results showed that berberine sulfate could significantly inhibit neomycin-induced HC and SGN damage. This study suggests that the fabricated organoid is highly biomimetic to the organ of Corti, which may provide an effective model for drug development, cell and gene therapy for SNHL.


Asunto(s)
Berberina , Órgano Espiral , Andamios del Tejido , Animales , Órgano Espiral/efectos de los fármacos , Ratones , Berberina/farmacología , Berberina/química , Andamios del Tejido/química , Organoides/metabolismo , Organoides/efectos de los fármacos , Impresión Tridimensional , Alginatos/química , Alginatos/farmacología , Gelatina/química , Gelatina/farmacología , Células Ciliadas Auditivas/efectos de los fármacos , Células Ciliadas Auditivas/metabolismo , Ingeniería de Tejidos , Alcohol Polivinílico/química , Alcohol Polivinílico/farmacología , Pérdida Auditiva Sensorineural , Ganglio Espiral de la Cóclea/efectos de los fármacos , Ganglio Espiral de la Cóclea/metabolismo
11.
Comput Biol Med ; 178: 108804, 2024 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-38941899

RESUMEN

Chronic atrophic gastritis (CAG), characterized by inflammation and erosion of the gastric lining, is a prevalent digestive disorder and considered a precursor to gastric cancer (GC). Coptis chinensis France (CCF) is renowned for its potent heat-clearing, detoxification, and anti-inflammatory properties. Zuojin Pill (ZJP), a classic Chinese medicine primarily composed of CCF, has demonstrated effectiveness in CAG treatment. This study aims to elucidate the potential mechanism of CCF treatment for CAG through a multifaceted approach encompassing network pharmacology, molecular docking, molecular dynamics simulation and experimental verification. The study identified three major active compounds of CCF and elucidated key pathways, such as TNF signaling, PI3K-Akt signaling and p53 signaling. Molecular docking revealed interactions between these active compounds and pivotal targets like PTGS2, TNF, MTOR, and TP53. Additionally, molecular dynamics simulation validated berberine as the primary active compound of CCF, which was further confirmed through experimental verification. This study not only identified berberine as the primary active compound of CCF but also provided valuable insights into the molecular mechanisms underlying CCF's efficacy in treating CAG. Furthermore, it offers a reference for refining therapeutic strategies for CAG management.


Asunto(s)
Coptis , Medicamentos Herbarios Chinos , Gastritis Atrófica , Simulación de Dinámica Molecular , Farmacología en Red , Humanos , Coptis/química , Medicamentos Herbarios Chinos/química , Medicamentos Herbarios Chinos/uso terapéutico , Medicamentos Herbarios Chinos/farmacología , Gastritis Atrófica/tratamiento farmacológico , Gastritis Atrófica/metabolismo , Simulación del Acoplamiento Molecular , Transducción de Señal/efectos de los fármacos , Proteína p53 Supresora de Tumor/metabolismo , Berberina/química , Berberina/uso terapéutico , Berberina/farmacología , Factor de Necrosis Tumoral alfa/metabolismo
12.
Org Biomol Chem ; 22(23): 4739-4747, 2024 06 12.
Artículo en Inglés | MEDLINE | ID: mdl-38804062

RESUMEN

Berberine (BBR), a widely used isoquinoline alkaloid derived from natural sources, exhibits aggregation-induced emission (AIE) characteristics and has biological applications such as in selective lipid droplet imaging and photodynamic therapy. However, natural BBR suffers from low fluorescence quantum yield (ΦF) and monotonous emission wavelength. In this paper, a series of C9-position-aryl-substituted berberine derivatives with a D-A structure were designed and synthesized. The electronic effect of the substitution groups can tune the intramolecular charge transfer (ICT) effect of the berberine derivatives, resulting in bluish green to NIR (508-682 nm) luminescence with AIE characteristics and enhanced ΦF up to 36% in the solid state. Interestingly, berberine derivatives containing an amino or a pyridyl group can exhibit fluorescence response to TFA. Cell imaging of the berberine derivatives was conducted using Caco-2 cancer cells, demonstrating their multi-color and efficient wash-free imaging capabilities. This work presents a new strategy for developing novel berberine derivatives with tunable AIE properties for application in biological imaging.


Asunto(s)
Berberina , Berberina/química , Berberina/farmacología , Berberina/síntesis química , Humanos , Células CACO-2 , Imagen Óptica , Colorantes Fluorescentes/química , Colorantes Fluorescentes/síntesis química , Estructura Molecular
13.
J Colloid Interface Sci ; 671: 354-373, 2024 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-38815372

RESUMEN

Berberine (Ber), an isoquinoline alkaloid, is a potential drug therapy for ulcerative colitis (UC) because of its anti-inflammatory activity, high biological safety, and few side effects. Nevertheless, its clinical application is hindered by its limited water solubility and low bioavailability. Currently, compared to synthetic nanocarriers, exosomes as carriers possess advantages such as low toxicity, high stability, and high specificity. Human placental mesenchymal stem cell-derived exosomes (HplMSC-Exos) have emerged as a promising drug delivery system, offering intrinsic anti-inflammatory and antioxidant activities. Therefore, we engineered MSC-Exos loaded with Ber (Exos-Ber) to enhance the solubility and bioavailability of Ber and for colon targeting, revealing a novel approach for treating UC with natural compounds. Structurally and functionally, Exos-Ber closely resembled unmodified Exos. Both in vitro and in vivo investigations confirmed the antioxidant and anti-inflammatory properties of Exos-Ber. Notably, Exos-Ber exhibited reparative effects on injured epithelial cells and reduced cellular apoptosis. Furthermore, Exos-Ber concurrently demonstrated anti-inflammatory and antioxidant activities, contributing to the mitigation of UC, possibly through its modulation of the MAPK signaling pathway. Overall, our findings demonstrate the potential of Exos-Ber as a promising therapeutic option for alleviating UC, highlighting its capacity to enhance the clinical applicability of Ber.


Asunto(s)
Berberina , Colitis Ulcerosa , Exosomas , Células Madre Mesenquimatosas , Exosomas/metabolismo , Exosomas/química , Colitis Ulcerosa/terapia , Colitis Ulcerosa/tratamiento farmacológico , Colitis Ulcerosa/patología , Berberina/farmacología , Berberina/química , Células Madre Mesenquimatosas/efectos de los fármacos , Células Madre Mesenquimatosas/metabolismo , Humanos , Animales , Ratones , Antiinflamatorios/farmacología , Antiinflamatorios/química , Apoptosis/efectos de los fármacos , Antioxidantes/farmacología , Antioxidantes/química , Células Cultivadas , Femenino , Tamaño de la Partícula , Supervivencia Celular/efectos de los fármacos
14.
Food Chem ; 454: 139830, 2024 Oct 01.
Artículo en Inglés | MEDLINE | ID: mdl-38820633

RESUMEN

In this study, the ß-cyclodextrin encapsulated betanin (BET@ß-CD) with improved thermal stability and retention as well as the berberine (BBR) with aggregate induced luminescence effect were incorporated into corn amylose (CA) biomatrix to develop colorimetric/fluorescent dual-channel smart film. Results shown that the added functional components were uniformly distributed in the film matrix. The high tensile strength (78.87%), low water solubility (31.15%) and water vapor permeability (1.24 × 10-10 g Pa-1 s-1 m-1) of the film predicted its acceptable stability. It was worth mentioning that the film displayed excellent responsiveness to volatile ammonia (0.025-25 mg/mL) with at least 4 times recyclability. Application experiment demonstrated that the film can achieve macroscopic dynamic monitoring of the freshness of shrimps stored at 25 °C, 4 °C, -20 °C under daylight (red to yellow) and UV light (yellow-green to blue-green). Thus, the study suggests an attractive and effective strategy for constructing dual-mode smart packaging materials for food freshness detection.


Asunto(s)
Berberina , Betacianinas , Embalaje de Alimentos , Almidón , beta-Ciclodextrinas , beta-Ciclodextrinas/química , Animales , Embalaje de Alimentos/instrumentación , Betacianinas/química , Berberina/química , Almidón/química , Solubilidad
15.
Biomed Pharmacother ; 176: 116798, 2024 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-38795642

RESUMEN

Cancer is one of the most lethal diseases all over the world. Despite that many drugs have been developed for cancer therapy, they still suffer from various limitations including poor treating efficacy, toxicity to normal human cells, and the emergence of multidrug resistance. In this study, the amphiphilic LHES polymers were prepared using hydroxyethyl starch (HES) and linoleic acid as starting materials. The content and substitution degree of linoleic acid groups in LHES polymers were analyzed. The LHES polymers were used for fabricating LHES-B nanoparticles carrying a linoleic acid modified berberine derivative (L-BBR). The LHES-B nanoparticles showed high drug loading efficiency (29%) and could quickly release L-BBR under acidic pH condition (pH = 4.5). Biological investigations revealed that LHES-B nanoparticles significantly inhibited the proliferation of HepG2 cells and exhibited higher cytotoxicity than L-BBR. In a transgenic Tg(fabp10:rtTA2s-M2; TRE2:EGFP-krasv12) zebrafish model, LHES-B nanoparticles obviously inhibited the expression of krasv12 oncogene. These results indicated that LHES carriers could improve the anticancer activity of L-BBR, and the synthesized LHES-B nanoparticles showed great potential as anticancer drug.


Asunto(s)
Berberina , Derivados de Hidroxietil Almidón , Ácido Linoleico , Nanopartículas , Proteínas Proto-Oncogénicas p21(ras) , Animales , Humanos , Animales Modificados Genéticamente , Antineoplásicos/farmacología , Antineoplásicos/química , Berberina/farmacología , Berberina/química , Proliferación Celular/efectos de los fármacos , Portadores de Fármacos/química , Liberación de Fármacos , Células Hep G2 , Derivados de Hidroxietil Almidón/farmacología , Derivados de Hidroxietil Almidón/química , Ácido Linoleico/química , Nanopartículas/química , Proteínas Proto-Oncogénicas p21(ras)/genética , Proteínas Proto-Oncogénicas p21(ras)/metabolismo , Pez Cebra , Modelos Animales de Enfermedad
16.
J Hazard Mater ; 473: 134680, 2024 Jul 15.
Artículo en Inglés | MEDLINE | ID: mdl-38795486

RESUMEN

Due to the bacteria resistant to various first-line antibiotics, it is urgent to develop efficient antibiotic alternatives and formulate multidimensional strategies. Herein, supramolecular Chinese medicine nanoparticles are synthesized by self-assembly of berberine (BBR) and chlorogenic acid (CGA), which exhibit higher inhibitory effect against Staphylococcus aureus and multidrug-resistant Staphylococcus aureus (MRSA) than ampicillin, oxacillin, BBR, CGA, as well as mixture of BBR and CGA (minimum inhibitory concentration, MIC = 1.5 µM). The inhibition by BBR/CGA nanoparticles (2.5 µM) reaches 99.06 % for MRSA, which is significantly higher than ampicillin (29.03 %). The nanoparticles with 1/2 MIC can also synergistically restore the antimicrobial activity of ampicillin against MRSA. Moreover, in vivo therapeutic outcome in the murine skin wound infection model suggests that the nanoparticles are able to promote wound healing. This study provides new insights in the application of Chinese medicines self-assembly for MRSA inhibition, as well as solutions for potential persistent clinical infections and drug deficiencies.


Asunto(s)
Antibacterianos , Berberina , Ácido Clorogénico , Staphylococcus aureus Resistente a Meticilina , Pruebas de Sensibilidad Microbiana , Nanopartículas , Berberina/farmacología , Berberina/química , Ácido Clorogénico/farmacología , Ácido Clorogénico/química , Animales , Nanopartículas/química , Staphylococcus aureus Resistente a Meticilina/efectos de los fármacos , Antibacterianos/farmacología , Antibacterianos/química , Ratones , Infecciones Estafilocócicas/tratamiento farmacológico , Staphylococcus aureus/efectos de los fármacos , Cicatrización de Heridas/efectos de los fármacos
17.
Biomacromolecules ; 25(6): 3345-3359, 2024 Jun 10.
Artículo en Inglés | MEDLINE | ID: mdl-38700942

RESUMEN

The management of diabetic ulcers poses a significant challenge worldwide, and persistent hyperglycemia makes patients susceptible to bacterial infections. Unfortunately, the overuse of antibiotics may lead to drug resistance and prolonged infections, contributing to chronic inflammation and hindering the healing process. To address these issues, a photothermal therapy technique was incorporated in the preparation of wound dressings. This innovative solution involved the formulation of a self-healing and injectable hydrogel matrix based on the Schiff base structure formed between the oxidized Bletilla striata polysaccharide (BSP) and hydroxypropyltrimethylammonium chloride chitosan. Furthermore, the introduction of CuO nanoparticles encapsulated in polydopamine imparted excellent photothermal properties to the hydrogel, which promoted the release of berberine (BER) loaded on the nanoparticles and boosted the antibacterial performance. In addition to providing a reliable physical protection to the wound, the developed hydrogel, which integrated the herbal components of BSP and BER, effectively accelerated wound closure via microenvironment regulation, including alleviated inflammatory reaction, stimulated re-epithelialization, and reduced oxidative stress based on the promising results from cell and animal experiments. These impressive outcomes highlighted their clinical potential in safeguarding the wound against bacterial intrusion and managing diabetic ulcers.


Asunto(s)
Quitosano , Hidrogeles , Polisacáridos , Cicatrización de Heridas , Quitosano/química , Quitosano/análogos & derivados , Quitosano/farmacología , Cicatrización de Heridas/efectos de los fármacos , Animales , Hidrogeles/química , Hidrogeles/farmacología , Polisacáridos/química , Polisacáridos/farmacología , Antibacterianos/farmacología , Antibacterianos/química , Terapia Fototérmica/métodos , Ratones , Humanos , Berberina/farmacología , Berberina/química , Ratas , Diabetes Mellitus Experimental/tratamiento farmacológico , Cobre/química , Cobre/farmacología , Masculino , Polímeros/química , Polímeros/farmacología , Indoles/química , Indoles/farmacología , Infección de Heridas/tratamiento farmacológico , Infección de Heridas/microbiología , Nanopartículas/química , Staphylococcus aureus/efectos de los fármacos , Nanopartículas del Metal/química
18.
J Nat Med ; 78(3): 590-598, 2024 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-38573419

RESUMEN

Baicalin and berberine are biologically active constituents of the crude drugs Scutellaria root and Coptis rhizome/Phellodendron bark, respectively. Baicalin and berberine are reported to combine together as a 1:1 complex that forms yellow precipitates by electrostatic interaction in decoctions of Kampo formulae containing these crude drugs. However, the structural basis and mechanism for the precipitate formation of this compound-compound interaction in aqueous solution remains unclarified. Herein, we searched for berberine derivatives in the Coptis rhizome that interact with baicalin and identified the chemical structures involved in the precipitation formation. Precipitation assays showed that baicalin formed precipitates with berberine and coptisine but not with palmatine and epiberberine. Thus, the 2,3-methylenedioxy structure may be crucial to the formation of the precipitates, and electrostatic interaction is necessary but is not sufficient. In this multicomponent system experiment, palmatine formed a dissociable complex with baicalin and may competitively inhibit the formation of berberine and coptisine precipitation with baicalin. Therefore, the precipitation formed by berberine and baicalin was considered to be caused by the aggregation of the berberine-baicalin complex, and the 2,3-methylenedioxy structure is likely crucial to the aggregation of the complex.


Asunto(s)
Berberina , Flavonoides , Berberina/química , Berberina/análogos & derivados , Flavonoides/química , Alcaloides de Berberina/química , Coptis/química , Agua/química , Estructura Molecular , Rizoma/química
19.
Fitoterapia ; 176: 105964, 2024 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-38663561

RESUMEN

Berberine was used as the lead compound in the present study to design and synthesize novel berberine derivatives by splicing bromine bridges of different berberine carbon chain lengths coupled nitric oxide donors, and their lipid lowering activities were assessed in a variety of ways. This experiment synthesized 17 new berberine nitric oxide donor derivatives. Compared with berberine hydrochloride, most of the compounds exhibited certain glycerate inhibitory activity, and compounds 6a, 6b, 6d, 12b and 12d showed higher inhibitory activity than berberine, with 6a, 6b and 6d having significant inhibitory activity. In addition, compound 6a linked to furazolidone nitric oxide donor showed better NO release in experiments; In further mechanistic studies, we screened and got two proteins, PCSK9 and ACLY, and docked two proteins with 17 compounds, and found that most of the compounds bound better with ATP citrate lyase (ACLY), among which there may be a strong interaction between compound 6a and ACLY, and the interaction force was better than the target drug Bempedoic Acid, which meaning that 6a may exert hypolipidemic effects by inhibiting ACLY; moreover, we also found that 6a may had the better performance in gastrointestinal absorption, blood-brain barrier permeability, Egan, Muegge class drug principle model calculation and bioavailability.


Asunto(s)
Berberina , Hipolipemiantes , Donantes de Óxido Nítrico , Berberina/farmacología , Berberina/análogos & derivados , Berberina/síntesis química , Berberina/química , Hipolipemiantes/farmacología , Hipolipemiantes/síntesis química , Hipolipemiantes/química , Donantes de Óxido Nítrico/farmacología , Donantes de Óxido Nítrico/síntesis química , Donantes de Óxido Nítrico/química , Humanos , Estructura Molecular , ATP Citrato (pro-S)-Liasa/antagonistas & inhibidores , ATP Citrato (pro-S)-Liasa/metabolismo , Proproteína Convertasa 9/metabolismo , Simulación del Acoplamiento Molecular , Animales , Barrera Hematoencefálica/efectos de los fármacos , Óxido Nítrico/metabolismo , Inhibidores de PCSK9
20.
Nano Lett ; 24(17): 5154-5164, 2024 May 01.
Artículo en Inglés | MEDLINE | ID: mdl-38602357

RESUMEN

Developing novel strategies for defeating osteoporosis has become a world-wide challenge with the aging of the population. In this work, novel supramolecular nanoagonists (NAs), constructed from alkaloids and phenolic acids, emerge as a carrier-free nanotherapy for efficacious osteoporosis treatment. These precision nanoagonists are formed through the self-assembly of berberine (BER) and chlorogenic acid (CGA), utilizing noncovalent electrostatic, π-π, and hydrophobic interactions. This assembly results in a 100% drug loading capacity and stable nanostructure. Furthermore, the resulting weights and proportions of CGA and BER within the NAs are meticulously controlled with strong consistency when the CGA/BER assembly feed ratio is altered from 1:1 to 1:4. As anticipated, our NAs themselves could passively target osteoporotic bone tissues following prolonged blood circulation, modulate Wnt signaling, regulate osteogenic differentiation, and ameliorate bone loss in ovariectomy-induced osteoporotic mice. We hope this work will open a new strategy to design efficient herbal-derived Wnt NAs for dealing with intractable osteoporosis.


Asunto(s)
Berberina , Ácido Clorogénico , Osteoporosis , Osteoporosis/tratamiento farmacológico , Animales , Ratones , Berberina/farmacología , Berberina/uso terapéutico , Berberina/química , Berberina/administración & dosificación , Berberina/farmacocinética , Ácido Clorogénico/química , Ácido Clorogénico/farmacología , Ácido Clorogénico/uso terapéutico , Ácido Clorogénico/administración & dosificación , Femenino , Humanos , Osteogénesis/efectos de los fármacos , Huesos/efectos de los fármacos , Huesos/patología , Nanoestructuras/química , Nanoestructuras/uso terapéutico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...